Table 2 Logistic regression analysis and additional predictive value of the model including neutrophil elastase (NE) and proteinase 3 (PR3) concentrations for patients with unfavorable outcome (mRS > 2) at 3 months in the whole study population (n = 342)

Logistic regression

 R² (Cox & snell)

0.326

0.385

 Age

OR = 1.002 (0.978–1.026), p = 0.893

OR = 1.005 (0.980–1.031), p = 0.686

 Sex (male)

OR = 1.495 (0.752–2.973), p = 0.252

OR = 1.789 (0.848–3.775), p = 0.127

 Onset-to-treatment time

OR = 1.007 (0.976–1.038), p = 0.678

OR = 1.006 (0.964–1.049), p = 0.795

 Admission NIHSS score

OR = 1.252 (1.177–1.331), p < 0.001^†

OR = 1.279 (1.196–1.368), p < 0.001^†

 Atrial fibrillation

OR = 0.916 (0.327–2.568), p = 0.868

OR = 0.873 (0.272–2.809), p = 0.820

 Intravenous thrombolysis

OR = 0.416 (0.210–0.825), p = 0.012^†

OR = 0.393 (0.190–0.814), p = 0.012^†

 Endovascular treatment

OR = 0.368 (0.155–0.877), p = 0.024^†

OR = 0.303 (0.118–0.779), p = 0.013^†

 SVO stroke

OR = 2.184 (0.618–7.718), p = 0.225

OR = 2.145 (0.538–8.554), p = 0.280

 Serum glucose

OR = 1.074 (0.989–1.167), p = 0.090

OR = 1.074 (0.979–1.178), p = 0.129

 Triglyceride

OR = 1.176 (0.984–1.404), p = 0.074

OR = 1.133 (0.920–1.397), p = 0.241

 Neutrophil-to-lymphocyte ratio

OR = 1.080 (1.006–1.160), p = 0.034^†

OR = 1.072 (0.991–1.159), p = 0.084

 Neutrophil elastase > 229.56 ng/mL

–

OR = 4.478 (2.344–8.554), p < 0.001^†

 Proteinase 3 > 388.77 ng/mL

–

OR = 2.805 (1.504–5.231), p = 0.001^†

ROC curve

 AUC, %

86.5

88.9

 p Value

Ref.

0.070

IDI index, %

 Total IDI

−

8.2 (5.2, 11.2)

 p value

Ref.

< 0.001

NRI index, %

 Categorical NRI

–

12.8 (3.1, 22.6)

 p value

Ref.

0.009

 Continuous NRI

–

100.0 (80.6, 119.4)

 p value

Ref.

< 0.001